Study of Topical Calcitriol in Children With Psoriasis
Primary Purpose
Psoriasis
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
calcitriol
Sponsored by

About this trial
This is an interventional treatment trial for Psoriasis focused on measuring dermatologic disorders, psoriasis, rare disease
Eligibility Criteria
PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Diagnosis of psoriasis At least 2 lesions with area at least 30-50 cm2 --Prior/Concurrent Therapy-- No other concurrent therapy for psoriasis No concurrent calcium supplements greater than 1,000 mg/day No concurrent prednisone or other drugs affecting serum or urine calcium levels --Patient Characteristics-- Renal: No high blood or urinary calcium levels Other: Not pregnant Negative pregnancy test Fertile patients must use effective contraception
Sites / Locations
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00006275
First Posted
September 11, 2000
Last Updated
June 23, 2005
Sponsor
National Center for Research Resources (NCRR)
Collaborators
Boston University
1. Study Identification
Unique Protocol Identification Number
NCT00006275
Brief Title
Study of Topical Calcitriol in Children With Psoriasis
Study Type
Interventional
2. Study Status
Record Verification Date
September 2000
Overall Recruitment Status
Completed
Study Start Date
July 2000 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
July 2000 (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
National Center for Research Resources (NCRR)
Collaborators
Boston University
4. Oversight
5. Study Description
Brief Summary
OBJECTIVES:
I. Determine the therapeutic efficacy and safety of topical calcitriol in children with psoriasis.
Detailed Description
PROTOCOL OUTLINE: Patients apply topical calcitriol in petrolatum on a psoriatic lesion daily. Patients also apply petrolatum without calcitriol to another psoriatic lesion daily.
Patients have both lesions photographed prior to therapy, monthly during therapy, and at the completion of therapy. Lesions are assessed weekly for 1 month and then every 2 weeks while on study. Blood samples are collected every 1 to 2 months and urine samples are collected every 2 weeks while on study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Psoriasis
Keywords
dermatologic disorders, psoriasis, rare disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Enrollment
20 (false)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
calcitriol
10. Eligibility
Sex
All
Minimum Age & Unit of Time
4 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
Diagnosis of psoriasis At least 2 lesions with area at least 30-50 cm2
--Prior/Concurrent Therapy--
No other concurrent therapy for psoriasis No concurrent calcium supplements greater than 1,000 mg/day No concurrent prednisone or other drugs affecting serum or urine calcium levels
--Patient Characteristics--
Renal: No high blood or urinary calcium levels
Other: Not pregnant Negative pregnancy test Fertile patients must use effective contraception
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael F. Holick
Organizational Affiliation
Boston University
Official's Role
Study Chair
12. IPD Sharing Statement
Learn more about this trial
Study of Topical Calcitriol in Children With Psoriasis
We'll reach out to this number within 24 hrs